Sleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people with insomnia is now being trialled to see if it can improve their sleep q
Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkins
Eli Lilly has acquired Prevail, a biotech focusing on gene therapies for neurodegenerative diseases including Parkinson's, in a deal potentially worth more than $1 billion.
Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from a small cohort of patients from a phase 2 trial.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.